An application generator for rapid prototyping of Ada real-time control software

The need to increase engineering productivity and decrease software life cycle costs in real-time system development establishes a motivation for a method of rapid prototyping. The design by iterative rapid prototyping technique is described. A tool which facilitates such a design methodology for the generation of embedded control software is described

Metal Organic Framework Modifications of Structural Fibers

A reinforced carbon composite can include a carbon sub­strate and a metal organic framework bonded to the carbon substrate. For example, a reinforced carbon composite can include a first layer, a second layer, and a resin adhered to the first layer and the second layer. The first layer can include a carbon substrate and a metal organic framework bonded to the carbon substrate. The second layer can include a carbon substrate and a metal organic framework bonded to the carbon substrate

Metal Organic Framework Modifications of Structural Fibers

A reinforced carbon composite can include a carbon sub­strate and a metal organic framework bonded to the carbon substrate. For example, a reinforced carbon composite can include a first layer, a second layer, and a resin adhered to the first layer and the second layer. The first layer can include a carbon substrate and a metal organic framework bonded to the carbon substrate. The second layer can include a carbon substrate and a metal organic framework bonded to the carbon substrate

Nano-drug Clinical Trials: Informed Consent and Risk Management Through Blockchain

Drug bearing nano-shells that can be utilized for targeted drug delivery have been shown to enhance the therapeutic index by increasing the dug concentration in diseased tissue and reducing the toxicity in normal tissue.  The controllability of the drug bearing shell size provides predictability measure for the amount of drug payload per shell which improves the administration of the therapeutic dose.  The FDA approved different formulations for clinical use in metastatic and recurrent breast cancer, among other diseases.  At the moment, some of these formulations are the subject of international clinical trials.  Informed consent is legally mandated in administering drug bearing nano-shells.  The risks of the new formulations, as with all new technologies, are not well known and are continue to be a subject of intensive research, thus exacerbating the existing informed consent legal issues, thus exacerbating the existing informed consent legal issues.  This short essay focuses on proposing a framework to mitigate liabilities administering a new formulation on nano-enabled drug carriers particularly when uncertainties of the benefits and damages are not fully known.